Standard
Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease : Experience from the Phase 3 ATTRACT study. / Hughes, Derralynn A; Nicholls, Kathleen; Sunder-Plassmann, Gere; Jovanovic, Ana; Feldt-Rasmussen, Ulla; Schiffmann, Raphael; Giugliani, Robert; Jain, Vipul; Viereck, Chris; Castelli, Jeffrey P; Skuban, Nina; Barth, Jay A; Bichet, Daniel G.
In:
American Journal of Medical Genetics. Part A, Vol. 179, No. 6, 2019, p. 1069-1073.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Hughes, DA, Nicholls, K, Sunder-Plassmann, G, Jovanovic, A
, Feldt-Rasmussen, U, Schiffmann, R, Giugliani, R, Jain, V, Viereck, C, Castelli, JP, Skuban, N, Barth, JA & Bichet, DG 2019, '
Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study',
American Journal of Medical Genetics. Part A, vol. 179, no. 6, pp. 1069-1073.
https://doi.org/10.1002/ajmg.a.61105APA
Hughes, D. A., Nicholls, K., Sunder-Plassmann, G., Jovanovic, A.
, Feldt-Rasmussen, U., Schiffmann, R., Giugliani, R., Jain, V., Viereck, C., Castelli, J. P., Skuban, N., Barth, J. A., & Bichet, D. G. (2019).
Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study.
American Journal of Medical Genetics. Part A,
179(6), 1069-1073.
https://doi.org/10.1002/ajmg.a.61105Vancouver
Hughes DA, Nicholls K, Sunder-Plassmann G, Jovanovic A
, Feldt-Rasmussen U, Schiffmann R et al.
Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study.
American Journal of Medical Genetics. Part A. 2019;179(6):1069-1073.
https://doi.org/10.1002/ajmg.a.61105Author
Hughes, Derralynn A ; Nicholls, Kathleen ; Sunder-Plassmann, Gere ; Jovanovic, Ana ; Feldt-Rasmussen, Ulla ; Schiffmann, Raphael ; Giugliani, Robert ; Jain, Vipul ; Viereck, Chris ; Castelli, Jeffrey P ; Skuban, Nina ; Barth, Jay A ; Bichet, Daniel G. / Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease : Experience from the Phase 3 ATTRACT study. In: American Journal of Medical Genetics. Part A. 2019 ; Vol. 179, No. 6. pp. 1069-1073.
Bibtex
@article{ae24c017d70f45d59ce59458f43286eb,
title = "Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study",
author = "Hughes, {Derralynn A} and Kathleen Nicholls and Gere Sunder-Plassmann and Ana Jovanovic and Ulla Feldt-Rasmussen and Raphael Schiffmann and Robert Giugliani and Vipul Jain and Chris Viereck and Castelli, {Jeffrey P} and Nina Skuban and Barth, {Jay A} and Bichet, {Daniel G}",
year = "2019",
doi = "10.1002/ajmg.a.61105",
language = "English",
volume = "179",
pages = "1069--1073",
journal = "American Journal of Medical Genetics, Part A",
issn = "1552-4825",
publisher = "JohnWiley & Sons, Inc.",
number = "6",
}
RIS
TY - JOUR
T1 - Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease
T2 - Experience from the Phase 3 ATTRACT study
AU - Hughes, Derralynn A
AU - Nicholls, Kathleen
AU - Sunder-Plassmann, Gere
AU - Jovanovic, Ana
AU - Feldt-Rasmussen, Ulla
AU - Schiffmann, Raphael
AU - Giugliani, Robert
AU - Jain, Vipul
AU - Viereck, Chris
AU - Castelli, Jeffrey P
AU - Skuban, Nina
AU - Barth, Jay A
AU - Bichet, Daniel G
PY - 2019
Y1 - 2019
U2 - 10.1002/ajmg.a.61105
DO - 10.1002/ajmg.a.61105
M3 - Journal article
C2 - 30920142
VL - 179
SP - 1069
EP - 1073
JO - American Journal of Medical Genetics, Part A
JF - American Journal of Medical Genetics, Part A
SN - 1552-4825
IS - 6
ER -
